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Merit:       Blood-brain barrier & cancer
     cell targeting
Ligands:  Hepcidin
Merit:       Iron recycling macrophage
     hepatocyte, enterocyte
     & cancer cell targeting?
Ligands:  Hb 
Merit:       Iron recycling macrophage
      targeting
Ligands:  Haem
Merit:      Macrophage, hepatocyte
     & cancer cell targeting
Ligands:  L-ferritin
Merit:       Drug carrier with pH-triggered
     release properties






Name	 Gene	 Characteristics	 Function	in	systemic	iron	
physiology	
Dysfunctional	phenotype	 Refs	
































Hepcidin	(also	known	as	LEAP-1)	 HAMP	 • 25	amino	acid	secreted	peptide	
• Produced	primarily	in	liver,	but	also	by	macrophages	and	several	other	cell	types	
• Master	regulator	of	iron	metabolism	





















































































• Exact	function	in	overall	iron	homeostasis	not	yet	clear	 • Homozygous	or	compound	heterozygous	mutations	in	FLVCR2	underlie	Fowler	syndrome,	a	syndrome	that	often	results	in	prenatal	lethality	marked	by	CNS	malformations,	including	hydrocephaly	and	hydranencephaly.	
39,321	
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Target	 Name	 Company	 Type	 Mechanism	 Indication	 Development	
status	
Trial	
identifiersa	BMP6	receptor	pathway	 LY3113593	 Eli	Lilly	and	Company	 Humanized	antibody	 Capture	of	BMP6	to	limit	hepcidin	expression	 Anaemia	 Phase	2	(lost	through	attrition	2016;	see	Further	information)	
NCT02604160	NCT02144285	
	 FMX-8	 FerruMax	Pharmaceuticals,	Inc	 HJV-Fc	fusion	protein	 Capture	of	BMP6	to	limit	hepcidin	expression	 Anaemia	 Phase	2	(terminated	trials	2016)	 NCT02228655	NCT01873534	Ferroportin	 LY2928057	 Eli	Lilly	and	Company	 Humanized	IgG4	antibody	 Binding	of	ferroportin	to	prevent	its	degradation	by	hepcidin,	thereby	stabilizing	ferroportin	expression	
Anaemia	 Phase	2	(removed	from	pipeline	2016)	 NCT01991483	NCT01330953	
Hepcidin	 M012	 Merganser	Biotech	Australia	Pty	Ltd.	 Peptide	 Hepcidin	mimetic	peptide	that	functions	as	a	hepcidin	agonist	 β-thalassemia,	low	risk	myelodysplastic	syndrome,	polycythaemia	vera	
Phase	1	 ACTRN12616000093482	
	 LJPC-401	 La	Jolla	Pharmaceutical	Company	 Peptide	 Hepcidin	mimetic	peptide	that	functions	as	a	hepcidin	agonist	 Iron	overload	 Phase	1	 ACTRN12616000132448	
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	 PTG-300	 Protagonist	Therapeutics	 Peptide	 Hepcidin	mimetic	peptide	that	functions	as	a	hepcidin	agonist	 Iron	overload	 preclinical	 n.a.		 PRS-080	 Pieris	Pharmaceuticals	GmbH	 Anticalin	 Bioengineered	lipocalin	that	captures	hepcidin	to	prevent	ferroportin	degradation	
Anaemia,	functional	iron	deficiency	 Phase	1b	 NCT02754167	NCT02340572	
	 NOX-H94	(lexaptepid	pegol)	 NOXXON	Pharma	AG	 L-RNA	spiegelmer	 L-stereoisomeric	RNA	aptamer	that	captures	hepcidin	to	prevent	ferroportin	degradation	
Anaemia	 Phase	2	 NCT02079896	NCT01691040	NCT01522794	NCT01372137	
	 12B9m	 Amgen	Inc	 Human	IgG2	antibody	 Capture	of	hepcidin	to	prevent	ferroportin	degradation	 Anaemia	 Preclinical	 n.a.	Iron	 Deferoxamine	(Desferal)	 Novartis	 small	molecule	 Chelation	of	iron	 Iron	intoxication	and	overload	 Marketed	 		 Deferasirox	(Exjade)	 Novartis	 Small	molecule	 Chelation	of	iron	 Iron	overload	 Marketed	 		 Deferiprone	(Ferriprox)	 ApoPharma	Inc.	 Small	molecule	 Chelation	of	iron	 Iron	overload	 Marketed	 		 DpC	 Oncochel	Therapeutics	 Small	molecule	 Chelation	of	iron	 Advanced	solid	tumours	 Phase	1	 NCT02688101	
	 52	
Matriptase-2	 IONIS-TMPRSS6-LRx	 Ionis	Pharmaceuticals	 Antisense	DNA	oligo-nucleotide	 Inhibition	of	MT-2	expression	to	promote	hepcidin	transcription	 β-thalassemia	 Preclinical	 n.a.		 ALN-TMP	 Alnylam	 siRNA	 Inhibition	of	MT-2	expression	to	promote	hepcidin	transcription	 β-thalassemia,	iron	overload		 Preclinical	 n.a.	Prolyl	hydroxylase	 FG-4592	/	ASP1517	(Roxadustat)	 FibroGen	Astellas	Pharma	AstraZeneca	
Small	molecule	 Inhibition	of	prolyl	hydroxylases	to	stabilize	HIFs	 Anaemia	in	chronic	kidney	disease	and	end-stage	renal	disease	
Phase	3	 NCT02805374	NCT02780726	NCT02779764	NCT02780141	
	 GSK1278863	/	GSK1278863A(Daprodustat)	 GlaxoSmithKline	 Small	molecule	 Inhibition	of	prolyl	hydroxylases	to	stabilize	HIFs	 Anaemia	in	chronic	kidney	disease	Wound	healing	
Phase	3	 NCT02879305	NCT02876835	NCT02829320	NCT02791763		 AKB-6548	(Vadadustat)	 Procter	&	Gamble	Akebia	Therapeutics	Mitsubishi	Tanabe	Pharma	
Small	molecule	 Inhibition	of	prolyl	hydroxylases	to	stabilize	HIFs	 Anaemia	in	chronic	kidney	disease	 Phase	3	 NCT02892149	NCT02865850	NCT02680574	NCT02648347	
	 BAY85-3934	(Molidustat)	 Bayer	HealthCare	AG	 Small	molecule	 Inhibition	of	prolyl	hydroxylases	to	stabilize	HIFs	 Anaemia	in	chronic	kidney	disease	 Phase	2	 NCT02312973	NCT02064426	NCT01975818	NCT02021409	
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Gene	therapy	to	highly	TfR1-expressing	tumours	 Solid	tumours	 Phase	1	 NCT01517464	
a	Most	recent	clinical	trials	(4),	ordered	by	date	of	registration	on	the	WHO	International	Clinical	Trials	Registry	Platform	(http://apps.who.int/trialsearch/Default.aspx)	
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Key	points	- Iron	metabolism	is	a	tightly	regulated	physiological	process	that	has	relatively	low	redundancy	and	its	deregulation	often	leads	to	iron	deficiency	or	iron	overload.	- Iron	deficiency	and	iron	overload	are	historically	associated	with	erythroid	disorders,	but	a	deregulated	iron	metabolism	has	also	been	implicated	in	numerous	ageing-related,	non-haematological	disorders	including	neurodegenerative	disorders,	atherosclerosis	and	cancer.	- Intracellular	iron	is	directly	involved	in	the	formation	of	reactive	oxygen	species	that	can	cause	cellular	oxidative	damage,	and	which	are	important	for	ferroptosis,	a	form	of	non-apoptotic	cell	death.	- The	internalization	of	iron	by	macrophages	can	modulate	macrophage	activity	towards	a	pro-inflammatory	phenotype,	which	is	likely	also	dependent	on	the	pathway	of	iron	intake.	- Agents	that	interfere	with	key	regulators	of	iron	metabolism	and	cellular	iron	trafficking	represent	a	promising	new	class	of	therapeutic	agents	for	various	diseases,	as	they	exploit	pathological	pathways	that	are	complementary	to	those	targeted	by	existing	treatments.	- Targeting	therapeutics	to	diseased	tissues	that	express	high	levels	of	transferrin	receptor	is	a	strategy	that	is	used	by	several	agents	under	clinical	development,	and	extension	of	this	strategy	towards	other	iron	metabolism-associated	cellular	transporters	may	be	advantageous.		
